Key result
Left-sided breast cancer radiotherapy linked to ~5-point decline in LVEF at 6 years.
Why the study?
The study was designed to investigate the long-term effects of adjuvant radiotherapy on cardiac function and biomarkers in early breast cancer patients over a six-year follow-up.
Does adjuvant radiotherapy without chemotherapy cause long-term subclinical deterioration in cardiac function and biomarkers in women with early breast cancer?
Cohort (n=73)
No
Does adjuvant radiotherapy without chemotherapy cause long-term subclinical deterioration in cardiac function and biomarkers in women with early breast cancer?
Absolute Event Rate: 60% vs 65%
p-value: p=0.002
Adjuvant breast cancer radiotherapy without chemotherapy results in subclinical, persistent impairment of left ventricular systolic and diastolic function, and elevated cardiac biomarkers at six years, particularly in left-sided disease.
May warrant serial LVEF monitoring after left-sided breast radiotherapy; leaves open causality and need for randomized confirmation.
Introduction: This prospective study investigated the long-term effects of adjuvant radiotherapy (RT) on cardiac function and biomarkers in early breast cancer patients over a six-year follow-up. Methods: Seventy-three women treated with RT alone, without chemotherapy, were included. Cardiac radiation doses were quantified, and echocardiography and serum biomarkers (high-sensitivity cardiac troponin T [hscTnT] and N-terminal pro-brain natriuretic peptide [proBNP]) were assessed before RT and at three- and six-years post-treatment. Results: Cardiac biomarkers increased significantly during follow-up. Median hscTnT rose from 4 to 6 ng/L (p<0.001), correlating with higher radiation doses to the heart in left-sided patients. ProBNP increased from 78 to 118 ng/L (p<0.001). Left ventricular (LV) systolic function declined in left-sided patients: ejection fraction decreased from 65% to 60% (p=0.002), global longitudinal strain from -18% to -17% (p=0.006), and stroke volume from 74 to 67 mL (p=0.015). Diastolic dysfunction also progressed, with impairments in isovolumic relaxation time and left atrial ejection fraction. Aromatase inhibitor (AI) use and higher mean heart dose were associated with greater cardiac impairment. Conclusion: Subclinical deterioration in cardiac function and elevated biomarkers were evident three years after RT and persisted at six years, suggesting permanent cardiac effects. Both radiation dose and AI therapy contributed to these changes. These findings underscore the importance of long-term cardiac monitoring and support the use of sensitive imaging and biomarkers to detect early radiotherapy-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Moisander et al. (2025) conducted a cohort in Early breast cancer (n=73). Adjuvant radiotherapy vs. Baseline (pre-radiotherapy) was evaluated on Left ventricular ejection fraction (LVEF) at 6 years in left-sided breast cancer patients (p=0.002). Adjuvant radiotherapy for left-sided breast cancer was associated with a significant decline in left ventricular ejection fraction from 65% to 60% over a six-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: